MindMed, Liechti Lab to Study Effects of Combining LSD, MDMA – Psych Congress Network

MindMed and the University Hospital Basels Liechti Lab on Tuesday announced plans to combine MDMA and LSD in a Phase 1 clinical trial scheduled to start in the fourth quarter of the year in Basel, Switzerland.

Some psychedelics, including psilocybin and LSD, have been shown to induce short-term, unpleasant effects for psychedelic-assisted therapy patients, such as negative thoughts, rumination, panic and paranoia. MDMA, meanwhile, has been found to induce feelings of well-being and trust.

Researchers conducting the study will pair LSD and MDMA within the same session to evaluate whether MDMA can reduce negative mood effects of LSD, making patients more comfortable and producing positive acute effects overall.

The potential of MDMA-LSD is to create a psychological state that may have the benefits of both substances and have longer lasting effects than standalone psilocybin or LSD, University Hospital Basels Liechti LabsMatthias Liechti, MD, MAS,said in a news release announcing the study. Inducing an overall primarily positive acute response during psychedelic assisted therapy is critical because several studies showed that a more positive acute experience is linked to a greater therapeutic long-term effect in patients.

The study is expected to take one year to complete.

See the rest here:

MindMed, Liechti Lab to Study Effects of Combining LSD, MDMA - Psych Congress Network